Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.

ABSTRACT:

Importance

Some patients with migraine, particularly those in primary care, require effective, well-tolerated, migraine-specific oral preventive treatments.

Objective

To examine the efficacy of atogepant, an oral, small-molecule, calcitonin gene-related peptide receptor antagonist, using 4 levels of mean monthly migraine-day (MMD) responder rates.

Design, setting, and participants

This secondary analysis of a phase 3, double-blind, placebo-controlled randomized clinical trial evaluated the efficacy and safety of atogepant for the preventive treatment of migraine from December 14, 2018, to June 19, 2020, in adults with 4 to 14 migraine-days per month at 128 sites in the US.

Interventions

Patients were administered 10 mg of atogepant (n = 222), 30 mg of atogepant

SUBMITTER: Lipton RB 

PROVIDER: S-EPMC9178435 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature